Friday, 21 Feb 2020


Date Typesort ascending Title Save
14 Nov 2017 Social Smoking Paradox in PsA - a UK study shows smoking was positively related to PsA risk in the general population, but…
13 Nov 2019 Social RT @EBRheum: #ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA Effect seems to stick around and favorab…
06 Nov 2017 Social RT @japaoli19: Significant reduction in immunosuppression load on uveitis pts with long term ADA use. #ACR17 @RheumNow #1115…
08 Feb 2020 Social The RheumNow Podcast is up! SF crystals, Stills biomarkers, best drugs for Psoriasis, Head drop, urticaria and FDG-PET vs MRA. Watch it here or join the 15,000 podcasters who listen every month on iTunes or here
06 Sep 2017 Social Psoriasis pruritus seen in >80%; metaanalysis 13 trials shows Anti Il-17, JAK inhib, ADA, apremilast reduce pruritus
01 Oct 2018 Social Psoriatic Arthritis in America June 2018 survey of 1,054 PsA patients shows 1/2 had sxs before 40, but only 1/4 were Dx. 64-92% saw 2-3 MDs to be Dx. 1/4 say their PsA is severe; 11% mild; and >2/3 have never been in remission
29 Oct 2018 Social European Commission (EC) has approved a label update for Cosentyx (secukinumab), now allowing up to 300 mg dosing and also includes 24-week Xray data with inhibition of progression of joint damage in PsA
18 Sep 2019 Social Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US.
22 Dec 2017 Social SPIRIT-P1 study of Taltz (IXE) in PsA shows that after initial 24 blind, PBO & ADA pts rerandomized to IXE q2 or q4 wks==ACR20/50/70 of 69%/55%/39% for q2wk and 69%/53%/40% for q4wk at 1 yr.
07 Nov 2017 Social RT @uptoTate: IBD assoc. w/ more severe SpA. Occurs w/ rate of 0.7/100 patient yrs/ 5 yrs in DESIR cohort. #ACR17 @RheumNow #2512 https://t…
01 Jan 2019 Social Full text review of psoriatic arthritis for NPs and PAs
23 Aug 2016 Social Structural progression is low (~5%) in early SpA; Sacroiliitis risk factors were B27, smoking & MRI SI inflammation
01 Nov 2019 Social Data on 14 261 PsA patients (from 11 European registries) startin TNFi therapy - shows that half (56%) were in DAS28 remission and 53% were ACR20 responders after 6 months, and 3/4 were still on TNFi at 1 year
08 Mar 2017 Social Nemolizumab (humanized anti-IL-31 receptor A mAb) shown to be effected in atopic dermatitis in NEJM paper
14 Jun 2018 Social RT @RonanTKavanagh: Although disease may be less severe at baseline in Ps A than in RA patients they fare less well at 3 months compared to…
11 Nov 2019 Social RT @DrKanikaMonga: What a pleasant surprise to be included in the #axSpA poster tour today — my research - showing an association with wor…
22 Apr 2016 Social Treatment options for active Ankylosing spondylitis: 1) Optimal dose NSAIDs; 2) TNF inhibitor; 3) Secukinumab; 4) ustekinumab (off label)
19 Oct 2017 Social Dr Ian McInnes at #APLAR2017 shows decreasing responses with TNFi switching in PsA.
13 Nov 2019 Social #ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention 1366 Self Joint exams 1120 Rheum burnout 1310 OA Hx 565 Enteropathic arthritis Recs 1823 MRE dx of SI 2773 Machine learning 2772 Antiinflammatory diet in RA 1359 Synovial Bx
07 Apr 2017 Social Dr. Ritchlin-30% psoriasis pts develop PsA, mechanisms unknown. enthesitis driven by biomechanical factors, arthritis involves IL-17, IL-23